logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Clears Varian Medical's Two Products - Quick Facts

Varian Medical Systems (VAR) Thursday said it has received an FDA 510(k) clearance for the latest version of its Vitesse real time planning for HDR brachytherapy. This is used to plan and perform high-dose-rate or HDR, ultrasound-guided brachytherapy treatments for prostate cancer.

Tim Clark, marketing manager for Varian BrachyTherapy, said, "This version of Vitesse reduces the number and complexity of steps involved in planning and completing a treatment. It eliminates the need for a data transfer to another software program, and avoids moving the patient to a CT scanner for images in the middle of the procedure.''

According to him, most clinicians will see a reduction in the amount of time needed to complete these treatments, often by as much as an hour and a half.

Separately, the company said the regulator also cleared its Edge radiosurgery suite, a new dedicated system for performing advanced radiosurgery using innovative real-time tumor tracking and motion management technologies.

According to the company, this enables fast, accurate delivery of stereotactic radiosurgery for treating lesions, tumors, and conditions anywhere in the body where radiotherapy is indicated, including tumors of the lung, prostate, spine and brain.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Boeing Co.(BA) reported a loss for the second-quarter 2016 compared to profit in the prior year, reflecting 787 cost reclassification and charges on the 747 program and the KC-46 Tanker program, partially offset by solid execution and higher volume. It cut its profit outlook for fiscal year 2016, while it reaffirmed annual revenue guidance. Automaker Fiat Chrysler Automobiles NV on Wednesday reported a 25 percent increase in profit for the second quarter from last year. However, quarterly net revenues and worldwide shipments declined from last year. Coca-Cola Co. (KO) posted a profit for the second-quarter that increased 11 percent from last year, while net operating revenues declined 5 percent. It is targeting full-year 2016 net share repurchases of $2.0 billion to $2.5 billion.
comments powered by Disqus
Follow RTT